August 2012
-
Assuming that MAP Pharmaceuticals’ Levadex inhaled dihydroergotamine for the treatment of migraine receives FDA approval, Allergan will market the product to pain specialists and neurologists in the US. MAP will handle marketing to primary care… Read more . . .
-
According to BASF, its new Ultraform N2320 003 PRO plastic for injection molding is specifically designed for medical applications with highly-stressed components, including dry powder inhalers. The new plastic will become commercially available in February… Read more . . .
-
California-based biotech company Ligand Pharmaceuticals has acquired CyDex Pharmaceuticals and its Captisol solubility-enhancing technology. CyDex’s pipeline includes a Captisol-enhanced budesonide/azelastine nasal spray. Ligand will operate CyDex as a wholly-owned subsidiary. Read the company’s press release. Read more . . .
-
A court in The Hague has ruled in favor of Sandoz and Hexal, both units of Novartis, agreeing that the Dutch portion of GSK’s European patent for Advair is not valid. GSK may appeal the… Read more . . .
-
The UK National Health Service has announced that a new MDI spacer developed through Health Enterprise East (HEE), an NHS "innovation hub," will be available through Vivo Smart Medical Devices. The collapsible spacer, called the… Read more . . .
-
MannKind Corporation has again received a complete response letter from the FDA in regards to its application for Afrezza inhaled insulin. A previous CRL was issued in March 2010, and the company resubmitted the NDA… Read more . . .
-
According to Alexza Pharmaceuticals, it plans to resubmit its NDA for AZ-004 (Staccato loxapine) for the treatment of agitation in schizophrenic patients in July 2011. The company received a complete response letter (CRL) for the… Read more . . .
-
CMO PharmaForm, a wholly-owned subsidiary of Akela Pharma, has hired J. Blair West, formerly of Bend Research and Azo Pharma, as Vice President of Pharmaceutical Operations. In addition, the company says, Feng Zhang will become… Read more . . .
-
According to reports, Lincoln Pharmaceuticals of Ahmedabad, India has been awarded an Indian patent for a nasal formulation of ondansetron hydrochloride intended to prevent nausea and vomiting for chemotherapy patients. The company says that it… Read more . . .
-
According to Archimedes Pharma, the Scottish Medicines Consortium has approved the company’s PecFent fentanyl pectin nasal spray for the treatment of breakthrough cancer pain for use in NHS Scotland. The product received marketing authorization in… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.